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miR-191We recently discovered that the protein phosphatase 2A (PP2A) B55α subunit (PPP2R2A) is under-expressed in
primary blast cells and is unfavorable for remission duration in AML patients. In this study, reverse phase protein
analysis (RPPA) of 230 proteins in 511 AML patient samples revealed a strong correlation of B55αwith a number
of proteins includingMYC, PKCα, and SRC. B55α suppression inOCI-AML3 cells by shRNA demonstrated that the
B subunit is a PKCα phosphatase. B55α does not target SRC, but rather the kinase suppresses protein expression
of the B subunit. Finally, the correlation between B55α and MYC levels reﬂected a complex stoichiometric
competition between B subunits. Loss of B55α in OCI-AML3 cells did not change global PP2A activity and the
only isoform that is induced is the one containing B56α. In cells containing B55α shRNA, MYC was suppressed
with concomitant induction of the competing B subunit B56α (PPP2R5A). A recent study determined that FTY-
720, a drug whose action involves the activation of PP2A, resulted in the induction of B55α In AML cells, and a
reduction of the B subunit rendered these cells resistant to FTY-720. Finally, reduction of the B subunit resulted
in an increase in the expression of miR-191-5p and a suppression of miR-142-3p. B55α regulation of these
miRs was intriguing as high levels of miR-191 portend poor survival in AML, and miR-142-3p is mutated in 2%
of AML patient samples. In summary, the suppression of B55α activates signaling pathways that could support
leukemia cell survival.
© 2014 Elsevier B.V.All rights reserved.1. Introduction
Acutemyeloid leukemia (AML) is a cancer of themyeloid hematopoi-
etic cells that accounts for ~80%of all adult acute leukemias. AML remains
a highly fatal disease given that relapse is common following standard
chemotherapy [4,6]. Hence, there is a great urgency to develop novel
targeted therapies with enhanced efﬁcacy. In this regard, strategies that
target signal transduction pathways supporting tumor cell growth and
survival are considered as one approach to optimize AML chemotherapy
[1–4].
Using reverse phase protein array technology (RPPA), we have re-
cently found that the expression of the protein phosphatase 2A (PP2A)utemyeloid leukemia; PKC, pro-
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).regulatory B subunit B55α (gene symbol PPP2R2A) is reduced in acute
myeloid leukemia cells compared to their normal hematopoietic cell
counterparts [5]. While the expression of B55α did not correlate with
overall survival, there was a positive correlation between its expression
and remission duration (RD) in AML patients. There is growing evidence
suggesting that PP2A isoforms can function as tumor suppressors [27,
28]. Such a role for B55α would be expected since it is a key regulator
of cell growth and survival, and it is down regulated in many cancers in-
cluding AML [5]. Furthermore, a number of reports have identiﬁed that
the B55α gene (located at chromosome 8p in humans) is deleted in
breast cancer [29], prostate cancer [30], primary plasma cell leukemia,
and multiple myeloma [31]. B55α has been implicated in regulating
the PP2A isoform that targets AKT [7]. In our dataset, the expression of
B55α negatively correlated with AKT phosphorylation, which was con-
sistent with a role for B55α as a negative regulator of AKT in AML cells
[5]. B55α appears to also be important in mitosis/cell cycle progression
with targets including CDK1 substrates [8] and FOXM1 [9].
The current study examined the potentialmechanistic underpinning
associated with the regulation of B55α expression and the possible role
1970 P.P. Ruvolo et al. / Biochimica et Biophysica Acta 1843 (2014) 1969–1977for the B subunit as a tumor suppressor in AML. The results presented
here identify survival proteins and pathways that appear to be activated
by the loss of B55α expression inmalignant hematopoietic cells, and, for
the ﬁrst time, we implicate B55α in the regulation of miR expression. In
doing so, we provide a clinically relevant model to explain why shorter
RD is more likely in AML patients with diminished B55α expression.
2. Material and methods
2.1. Patient samples
Peripheral blood and bone marrow specimens were collected prior
to therapy from 511 patients with newly diagnosed AML at the Univer-
sity of Texas MD Anderson Cancer Center between September of 1999
and March of 2007. The samples were acquired (lab protocol 01-473)
during routine diagnostic assessments and analyzed (analysis protocol
05-0654) in accordance with the regulations approved by the
Institution's Investigational Review Board. Informed consent was ob-
tained in accordance with the Declaration of Helsinki. The patient char-
acteristics and sample preparation have been described previously [14].
2.2. RPPA
Proteomic proﬁling of the AML patient samples was accomplished
using RPPA. The method and validation of the technique has been
described previously [5,14].
2.3. Cell treatment and cytotoxicity assessments
Cells were treated with the indicated doses of cytarabine (AraC),
FTY-720, and dasatinib (all purchased from LC Laboratories, Woburn,
MA, USA) or MK-2206 (Selleck Chemicals, Houston, TX) for various
times. For cell viability and apoptosis, the cells were washed in PBS,
resuspended in binding buffer containing annexin V (Roche Diagnos-
tics, Indianapolis, IN, USA). The percentages of viable and dead cells
(i.e., annexin V negative or positive, respectively) were assessed by
analytical ﬂow cytometry using a Becton Dickinson LSR II ﬂow
cytometer (Becton Dickinson, San Jose, CA, USA). Counting beads were
used to determine total cell number.
2.4. B55α (PPP2R2A) knockdown cells
PPP2R2Awas knocked down by lentiviral transduction using a gene-
speciﬁc shRNAmir transfer vector (clone V3LHS_377709, targeting
residues 1563–1581 on RefSeq NM_002717.3 and residues 1295–1313
on RefSeq NM_001177591.1) (Open Biosystems, Huntsville, AL, USA).
The lentivirus was prepared by co-transfection of HEK293T cells (ATCC,
Manassas, VA, USA)with an equalmolarmix of transfer vector and pack-
aging plasmids (psPAX2 and pMD2.G from Addgene, Cambridge, MA,
USA) using a JetPrime transfection reagent as directed by the manufac-
turer (Polyplus, Illkirch, France). Fresh lentiviral supernatants were
passed through 0.45 micron pore surfactant-free cellulose acetate mem-
branes and then used at once to infect OCI-AML3 cells by incubation
overnight at 37 °C under 5% CO2. OCI-AML3 cells were a kind gift from
Mark Minden (Ontario Cancer Institute; Toronto, Canada). Infected cells
were identiﬁed by ﬂuorescence microscopy by green ﬂuorescent protein
(GFP) expression and then selected with puromycin (Life Technologies,
Grand Island, NY) starting at 1 μg/ml. In parallel, all cellswere transduced
using lentivirus delivering a non-speciﬁc control (Open Biosystems).
Knockdown was veriﬁed by Western blot analysis and real time PCR.
To suppress B55α in OCI-AML3 cells, control (ON-TARGETplus Non-
targeting Pool; Dharmacon) or B55α siRNA (Smartpool ON-TARGETplus
PPP2R2A; Dharmacon) was introduced into the cells. For both siRNAs,
100 nM of the siRNA was introduced into cells by electroporation
using an Amaxa device (Lonza). Lonza Reagent T was used for theOCI-AML3 cells for electroporation. Cells were collected at 48 h and
knock down was veriﬁed by Western blot analysis.
2.5. Gene and miR expression analysis
Gene expression analysis usingqRT-PCRwas performed as previous-
ly described [5]. Real-time PCR was conducted using an ABI Prism 7700
Sequence Detection System (Life Technologies). We ran duplicate 25 μl
reactions containing 0.5 μl cDNA, and the reactions were repeated if the
Ct values were more than 0.25 cycles apart. As primers and probes we
used TaqMan Gene Expression Assays (Life Technologies) speciﬁc for
the genes of interest in this study (Supplementary Table 1) as directed
by themanufacturer.We used ABL as a housekeeping gene to normalize
gene expression. To calculate the relative abundance (RA) of each
transcript of interest relative to that of ABL, the following formula was
employed: RA = 100 × 2[−ΔCt], where ΔCt is the mean Ct of the tran-
script of interest minus the mean Ct of the transcript for ABL.
2.6. Confocal immunoﬂuorescence microscopy
OCI-AML3 cells expressing non-speciﬁc control shRNA and cells
expressing B55α shRNA were centrifuged onto slides using a Statspin
Cytofuge 12 (Cytofuge, Westwood, MA, USA), ﬁxed with 4% paraformal-
dehyde andpermeabilizedwith 100%methanol. The cellswere incubated
in blocking solution (3% FBS/1% BSA/1× PBS). B55αmouse monoclonal
antibody (Santa Cruz Biotechnology) was added to cells at a 1:200 dilu-
tion in blocking solution. Cells were washed and secondary antibody
(Alexa 594-tagged donkey anti-mouse, Life Technologies) was added in
blocking solution. Cells were washed, stained with 4′,6-diamidino-2-
phenylindole (DAPI, an nuclear stain, Life Technologies), washed again,
and visualized using an Olympus FV1000 Laser Scanning Confocal micro-
scope (Center Valley, PA, USA).
2.7. miR expression proﬁles
DNA microarray analysis was performed using the Human OneArray
miRNAv2 (PhalanxBiotech, Belmont, CA, USA). RNAquality and integrity
were determined utilizing an Agilent 2100 Bioanalyzer (Agilent Technol-
ogies, Palo Alto, CA, USA) and absorbance at A260, A280 and A230. The
RNA was enriched using a 2-step process with Nanosep 100k (Pall, Port
Washington, NY, USA) and Vivaspin 500 3k ﬁlters (Sartorius, Göttingen,
Germany). Small RNA was labeled with Cy5-ULS (Kreatech Diagnostics,
Amsterdam, Netherlands). Labeled RNA was hybridized at 37 °C over-
night using miRNA OneArray Hybridization Chamber with 1× OneArray
Hybridization Buffers I and II (Phalanx Biotech). After hybridization, the
arrays were washed according to the OneArray protocol. Raw intensity
signals for each microarray were captured using a Molecular Dynamics
Axon 4100A scanner and assessed using GenePixPro software. The data
from all microarrays in each experimental set was then passed to
RLimma, RColorBrewer, andGeneﬁlter for combining technical replicates
and performing statistical analyses.
2.8. Statistical analyses
For RPPA, super curve algorithms were used to generate a single
value from the ﬁve serial dilutions [15]. Loading control and topograph-
ical normalization procedures accounted for protein concentration and
background staining variations [16]. Analysis using unbiased clustering
perturbation bootstrap clustering, and principle component analysis
was then done as fully described in a previous publication [17]. Vari-
ables were divided into sixths based on the range of expression of all
511 samples. Comparison of the protein levels between paired samples
wasdone byperformingpaired Student t-test. Association betweenpro-
tein expression levels and categorical clinical variables were assessed in
R using standard Student t-tests, linear regression, or mixed effects
linear models. Association between continuous variable and protein
Fig. 1. Proteins correlated with B55α PP2A expression. Negative and positive correlation
from a list of 230 proteins also assayed using the same reverse phase proteomics analysis
on the same samples; Pearson correlation coefﬁcient R N 0.2, p b 0.001 or b 0.001.
1971P.P. Ruvolo et al. / Biochimica et Biophysica Acta 1843 (2014) 1969–1977levels were assessed by using the Pearson and Spearman correlation and
linear regression. Bonferroni corrections were done to account for multi-
ple statistical parameters for calculating statistical signiﬁcance (GraphPad
Prism version 6.0 software, GraphPad Software, Inc., San Diego, CA, USA).
Where indicated, the results are expressed as themean value of triplicate
samples ± SD (error bars). All means ± SD for triplicate samples were
calculated with Microsoft Excel 2003 SP2 software (Microsoft Corpora-
tion, Seattle, WA). In all statistical analyses, the results were considered
statistically signiﬁcant when p ≤ 0.05 using the Student t-test.3. Results
3.1. B55α protein levels correlate strongly with a distinct set of signaling
proteins in AML blast cells
We have previously used RPPA to study the PP2A substrate speciﬁc-
ity deﬁning B55α protein in AML blast cells to examine the role of theFig. 2. Expression of B55α in AML primary cells and cell lines. Protein lysate (200,000 cell
equivalents) from ﬁve primary AML patient blast cells and ﬁve AML cell lines including
OCI-AML3, HL60, KG1a, THP-1, and U937 was subject to SDS/PAGE and Western blot
analysis performed for B55α and Tubulin. Ratio of B55α to Tubulin was determined by
densitometric analysis of the bands depicted in the ﬁgure.PP2A subunit in regulating AKT signaling [5]. While B55α was shown
to be an important regulator of AKT in AML, the role of the phosphatase
in regulating other targets was not clear. RPPA was used to examine
correlations of B55α with 230 proteins in the blast cells from 511 AML
patients. As shown in Fig. 1, over 70 proteins showed a statistically
signiﬁcant (p b 0.0001) correlation with B55α, and it was positively
correlated with myelocytomatosis viral oncogene homolog (MYC)
expression. PP2A has been shown to regulate MYC expression [21]. In
addition to our ﬁnding that B55α appears to be associated with MYC
regulation, the B subunit family B56 has also been implicated in this
process via its members B56α (gene symbol PPP2R5A) [21] and B56δ
(gene symbol PPP2R5D) [22]. It is also interesting to note that MYC
supports pro-death pathways when partnered with the early growth
response family member 1 [20], which was also positively correlated
with the expression of B55α in the AML patient samples (Fig. 1).Fig. 3. Suppression of B55α in OCI-AML3 cells. (a) RNA was isolated from OCI-AML3 cells
containing control (NS, non-speciﬁc) lentiviral plasmid or cells containing B55α shRNA
lentiviral plasmid. Gene expression was determined by qRT-PCR using ABI assay primers
for the B subunit and 18S RNA as described in the Materials and methods section. The t-
test was performed to determine statistical signiﬁcance (p b 0.0001). (b) Protein lysate
(200,000 cell equivalents) from OCI-AML3 cells containing control (NS) lentiviral plasmid
or cells containing B55α shRNA lentiviral plasmid was subject to SDS/PAGE and Western
blot analysis performed for B55α, p-AKT (S473), and Tubulin. Ratio of B55α or p-AKT to
Tubulin was determined by densitometric analysis of the bands depicted in the ﬁgure.
Fig. 4. Imaging of B55α in OCI-AML3 cells by confocal immunoﬂuorescencemicroscopy. B55αwas imaged in OCI-AML3 cells containing control (NS) lentiviral plasmid or cells containing
B55α shRNA lentiviral plasmid by confocal IF microscopy as described in the “Materials and methods”. Images are Brightﬁeld (gray), DAPI stained nuclei (blue), and B55α stained (red).
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SRC phosphorylation
We previously have found by RPPA analysis that B55α expression is
variable among AML patient samples [5]. To compare B55α expression
levels in primary AML samples andAML cell lines, expression of B55α in
ﬁve primary AML patient samples and ﬁve AML cell lines wasmeasured
by Western blot analysis (Fig. 2). AML cell lines included OCI-AML3,
HL60, KG1a, THP-1, and U937. Consistent with our previous study,
when normalized to Tubulin expression of the B subunit is variable
among the patient samples. As shown in Fig. 2, this is also the case
for the AML cell lines. The cell lines in general express more B55α
compared to the primary samples. Expression of the B subunit in OCI-
AML3 cells was two to ﬁve fold higher compared to the AML patient
samples (Fig. 2). Lentivirus was used to deliver plasmid containing
shRNA against B55α or a control shRNA into OCI-AML3 cells. The con-
trol shRNA targeted a non-human gene (i.e., GFP). The B55α shRNA
cells had approximately 60% reduction in B55α gene transcript as dem-
onstrated by qRT-PCR (Fig. 3a) and protein as determined by Western
blot analysis (Fig. 3b). Consistent with the clinical correlations with
AKT activation in the AML patient cohort previously published [5],
reduction of B55α results in increased AKT phosphorylation (Fig. 3b).
We examined the suppression of B55α in the OCI-AML3 shRNA
transductants using confocal immunoﬂuorescence microscopy. In the
images in Fig. 4, the B55α is indicated by red ﬂuorescence and nuclei
are designated by blue ﬂuorescence. In the cells expressing the control
shRNA, B55α is abundant and it is primarily localized in the cytoplasm.
Conversely, in the cells expressing B55α shRNA, the B55α appears to
have very little ﬂuorescence intensity.
Our RPPA data showed a strong, negative correlation between B55α
and PKCα serine 657 phosphorylation (Fig. 1). Serine 657 phosphoryla-
tion of protein kinase Cα (PKCα) was determined by Western blot
analysis in OCI-AML3 cells expressing control shRNA or B55α shRNA.
Consistent with having a role as a PKCα phosphatase, there is a nearly
2-fold increase in PKCα phosphorylation in the cells where B55α was
suppressed (Fig. 5a).
Of the proteins examined by RPPA, B55αdisplayed the strongest neg-
ative correlation with SRC phosphorylated at tyrosine 527 or tyrosine
416 (Fig. 1). Therefore, it is possible that B55α either induces a tyrosinephosphatase or suppresses the tyrosine kinase that phosphorylates SRC.
To test this hypothesis, the OCI-AML3 cells were treated with 100 nM
dasatinib (a tyrosine kinase inhibitor that has been shown to inhibit
SRC) [32] for 24 h. As shown in Fig. 5b, this drug markedly inhibited the
phosphorylation of SRC at tyrosine 416. The dasatinib-treated cells also
showed a 1.7-fold increase in the expression of B55α, which suggested
a potential role for SRC as a regulator of B55α (Fig. 5b).
3.3. Loss of B55α induces competing B subunit B56α with concomitant
suppression of MYC expression
We have observed in acute lymphoblastic leukemia cells that
B55α levels were increased in cells where expression of B56α was
suppressed [24]. B56α expression was compared in OCI-AML3 cells
with control shRNAplasmid andOCI-AML3 cellswith B55α shRNAplas-
mid. As shown in Fig. 6a, the cells with suppressed B55α displayed an
almost 2-fold increase in B56α.
The protein stability of MYC has been shown to be regulated by
B56α [21]. B56α de-phosphorylation of the PEST sequence in MYC
protein results in ubiquitination and proteasomal degradation of the
transcription factor. A Western blot analysis revealed that the OCI-
AML3 cells with the control shRNA expressed nearly 2-fold more MYC
compared to the cells with the B55α shRNA (Fig. 6a). The reduction of
MYC expression by the suppression of B55α was not due to transcrip-
tional mechanisms since the qRT-PCR results of gene expression levels
in the control and B55α shRNA cells were similar (Fig. 6b).
To test for effects of lentivirus on B55α suppression, siRNA was used
to suppress the B subunit in the OCI-AML3 cells. Control siRNAwithmin-
imal homology to human gene sequences (Dharmacon Non-targeting
SMARTPool; 100 nM) or B55α siRNA (Dharmacon PPP2R2A SMARTPool;
100 nM) was introduced into cells by electroporation and cells were
collected at 48 h. B55α siRNA was able to reduce levels of the B subunit
by 60% compared to cells treated with control siRNA (Fig. 6c). Consistent
with results observed with the lentiviral shRNA (Fig. 4), reduction of the
B subunit by siRNA resulted in reduced expression of MYC and increased
expression of B56α (Fig. 6c). Consistent with a model where MYC
protein is degraded in response to dephosphorylation, serine 58/62
phosphorylation of MYC was reduced in the OCI-AML3 cells treated
with B55α siRNA (Fig. 6c). In addition, phosphorylation of PKCα was
Fig. 5. Effect of B55α reduction on PKCα and SRC in OCI-AML3 cells. Protein lysate
(200,000 cell equivalents) from OCI-AML3 cells containing control (NS) lentiviral plasmid
or cells containing B55α shRNA lentiviral plasmid was subject to SDS/PAGE andWestern
blot analysis performed for p-PKCα (a), PKCα (a), p-SRC Y416 (b), SRC (b), B55α (b),
PP2A/C (b), and Tubulin (a and b). Ratios were determined by densitometric analysis of
the bands depicted in the ﬁgure.
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siRNA (data not shown).
A molybdate dye assay measuring the dephosphorylation of
phosphopeptides by immunoprecipitated PP2A was used to determine
the effect of B55α expression on cellular PP2A activity. Using this assay,
we observed that the PP2A activity was similar in cells despite the
reduction of B55α expression (Fig. 7). Considering that PP2A phospha-
tase is an obligate hetero-trimer [18,19], it is likely that expression of
B56α and other PP2A B subunits that would be induced with B55α
loss would sustain PP2A activity in the B55α shRNA cells.
3.4. OCI-AML3 cells with B55α shRNA exhibit reduced the sensitivity to
FTY-720
Yang and colleagues recently demonstrated that the PP2A activating
drug FTY-720 could induce B55α and apoptosis in Kasumi-1 and HL60AML cells, as well as primary c-KIT-mutant AML cells [23]. However, it
is not known if the FTY-720-induced apoptosis required the induction
of B55α. OCI-AML3 cells were treated with 5 μM FTY-720 for 48 h. The
suppression of B55α in the B55α shRNA cells resulted in a marked,
statistically signiﬁcant protection against FTY-720-induced apoptosis
(Fig. 8). These results suggested that B55α expression was necessary,
but not sufﬁcient for FTY-720-induced apoptosis. Considering the effect
of B55α as a negative regulator of AKT and PKC survival pathways, it
could be expected that the inhibition of B55α in B55α shRNA cells
would render them more resistant to certain drugs. OCI-AML3 cells
with B55α shRNA or control shRNA were treated with the chemothera-
peutic agent AraC for 48 h. The suppression of B55α resulted in a statis-
tically signiﬁcant protection of B55α cells from 1 and 3 μMdoses of AraC
(Fig. 8).
3.5. Suppression of B55α affects the expression of miRs in OCI-AML3 cells
It would be reasonable to expect that B55α could inﬂuence gene
expression considering that it has been shown to regulate transcription
factors such as FOXM1 [9]. Since B55α levels appear to inﬂuence the
expression of MYC (Fig. 9a), we would also suggest the possible control
of miR expression by this protein given that MYC has been shown to
regulate a number of miRs including those in the miR 17-92 [33]. RNA
was isolated from OCI-AML3 cells expressing control NS shRNA and
OCI-AML3 cells expressing B55α shRNA. Gene expression proﬁling
revealed few major changes in mRNA expression in the cells when
B55α was suppressed. The reduction of B55α in OCI-AML3 cells leads
to a statistically signiﬁcant increase of N2-fold (i.e., log2 difference of
1 or greater) expression in only 10 genes (Fig. 9). There was also a sta-
tistically signiﬁcant decrease of N2-fold in only seven genes including
the B55α (PPP2R2A) gene. The gene most affected by the reduction of
B55α was GLIPR1 (whose expression was increased by N100-fold;
Fig. 9). GLIPR1 has been shown to be a tumor suppressor in solid tumors
[26], so this observed effect would suggest that the loss of B55αmight
have some protective effects. However, despite the increased transcrip-
tion of theGLIPR1 gene, therewas no difference in protein expression in
the OCI-AML3 cells with B55α shRNA (data not shown).
While effects on gene transcription were minimal in response to
suppression of B55α, reductionof B55α affected expression of a number
of miRs (Fig. 10a and b). Only three miRs were signiﬁcantly elevated by
at least 2-fold in response to suppression of the B55α. These were miR-
4290, miR-4508, andmiR-191-5p (Fig. 10a). Not much has been report-
ed aboutmiR-4290 andmiR-4508, butmiR-191-5p has been implicated
as being detrimental for patient survival in AML [10]. Reduction of B55α
in the OCI-AML3 cells had a greater effect in the suppression of a num-
ber ofmiRs. At least 32miRswere signiﬁcantly reduced by at least 2-fold
in the B55α shRNA cells (Fig. 10b). A reduction of N200-fold was
observed for miR-1260a. Unfortunately, not much has been reported
about this miR so the signiﬁcance of its reduction in the cells is not
clear. Among the other miRs that were suppressed are miR-142-3p
andmiR-142-5p (Fig. 10b). ThesemiRs have been shown to bemutated
in lymphoma and AML [12,13]. MiR-142-3p has been implicated in
control ofmyeloid differentiation by amechanism involving TGF-beta ac-
tivated kinase 1/MAP3K7 binding protein 2 (AB2) and Cyclin T2 (CCNT2)
[11]. While there was not a signiﬁcant increase in TAB2 in the OCI-AML3
cells with B55α shRNA, there was an increase in CCNT2 gene expression
(log2 increase of 0.4; p = 0.004).
4. Discussion
We have previously determined that B55α expression is positively
correlated with RD [5]. Consistent with a role for the B subunit as a pos-
itive regulator of stress signaling in leukemia cells, the suppression of
B55α in OCI-AML3 cells renders these cells resistant to the conventional
chemotherapeutic drug AraC and the PP2A activating drug FTY-720
(Fig. 8). The suppression of B55α in the leukemia cells also induced
Fig. 6. Effect of B55α suppression on MYC and B56 α in OCI-AML3 cells. (a) Protein lysate (200,000 cell equivalents) from OCI-AML3 cells containing control (NS) lentiviral plasmid or cells
containing B55α shRNA lentiviral plasmid was subject to SDS/PAGE andWestern blot analysis performed for B56α, MYC, and Tubulin. Ratios were determined by densitometric analysis of
the bands depicted in the ﬁgure. (b) RNA was isolated from OCI-AML3 cells containing control (NS) lentiviral plasmid or cells containing B55α shRNA lentiviral plasmid. Gene expression
was determined by qRT-PCR using ABI assay primers for MYC, B56α, and 18S RNA as described in the “Materials and methods”. The Student t-test was performed to determine statistical
signiﬁcance (p N 0.05 in all cases). (c) Protein lysate (200,000 cell equivalents) from OCI-AML3 cells treated with control siRNA or B55α siRNA was subject to SDS/PAGE andWestern blot
analysis performed for B55α, B56α, MYC, p-MYC, and Tubulin. Ratios were determined by densitometric analysis of the bands depicted in the ﬁgure.
Fig. 7. Effect of B55α suppression on PP2A activity in OCI-AML3 cells. PP2A activity was
determined in OCI-AML3 cells containing control (NS) lentiviral plasmid or cells contain-
ing B55α shRNA lentiviral plasmid by spectrophotometric analysis ofmolybdate dye assay
using phospopeptide substrate as described in the “Materials and methods”. Activity is
presented as absorbance units.
1974 P.P. Ruvolo et al. / Biochimica et Biophysica Acta 1843 (2014) 1969–1977the phosphorylation of AKT (Fig. 3b). Thus, B55αmay have tumor sup-
pressor functions in AML, and strategies to activate this PP2A isoform
could be a novel target for AML chemotherapy.
Cells that are deﬁcient in B55α activity could be prone to becoming
malignant by a number of diversemechanisms including the inability to
activate p53, aberrant activation of survival signaling, and the deregula-
tion of the cell cycle and mitosis [8,9,33–35]. For example, B55α is a
critical regulator of CDC25 andWEE1which controls how cells progress
through the cell cycle [34]. Schmitz and colleagues have demonstrated
that B55α regulates cellular reassembly mechanisms during mitotic
exit in cooperation with importin-β1 [8]. In addition, B55α regulates
temporal function of FOXM1 during the cell cycle. FOXM1 is normally
only active during G2 but depletion of B55α results in premature activa-
tion of the transcription factor in G1/S [9]. A recent report has indicated
that B55α is central to activation of p53 via a reactive oxygen species-
dependent mechanism in response to glutamine deprivation. Further-
more, Reid et al. found that B55α can regulate cell metabolism, since
it can modulate a p53-dependent metabolic adaptation to glutamine
deprivation [33].
Our RPPA data revealed that the expression of B55αwas negatively
correlated with the phosphorylation of the cell survival kinases SRC and
PKCα (Fig. 1). We speculate that B55α likely acts to dephosphorylate
PKCα, since cells with B55α shRNA exhibited an almost 2-fold increase
in phosphorylation of the kinase (Fig. 5a). There was no difference in
phosphorylation of SRC in OCI-AML3 cells with B55α shRNA (data not
Fig. 8. Effect of B55α suppression on drug resistance in OCI-AML3 cells. OCI-AML3 cells
containing control (NS) lentiviral plasmid or cells containing B55α shRNA lentiviral
plasmid were treated with vehicle (0.1% DMSO), 1 μM AraC, 3 μM AraC, or 5 μM FTY-720
for 48 h. Total viable cells were determined by analytical ﬂow cytometry as described in
the “Materials and methods”. The Student t-test was performed to determine statistical
signiﬁcance (*, p = 0.014; **, p = 0.006, ***, p b 0.001).
1975P.P. Ruvolo et al. / Biochimica et Biophysica Acta 1843 (2014) 1969–1977shown). However, if SRC was inhibited in these cells using dasatinib,
then the expression of B55α was increased by almost 2-fold (Fig. 5b).
Inhibition of SRC did not affect expression of catalytic PP2A C subunit
(Fig. 5b), so the induction was not due to increased PP2A catalytic
core. The mechanism of how SRC negatively regulates B55α certainly
merits further characterization.
The regulation ofMYC by PP2A has beenwell studied but it is a B55α
of another family (i.e. B56α) that has been shown to regulate MYC
degradation [21]. OCI-AML3 cells with B55α shRNA displayed a N2-
fold increase in B56α suggesting that MYC induction in the cells was
due to stoichiometric effects that result from competition between the
B subunits (Fig. 6a and c). Consistent with degradation of MYC in
response to B56α mediated dephosphorylation, suppression of B55α
also resulted in decreased phosphorylation of MYC at serines involved
in proteolytic control (i.e. serine 58/62; Fig. 6c).Fig. 9. Effect of B55α suppression on gene expression in OCI-AML3 cells. RNA was isolated from
lentiviral plasmid. DNA microarray analysis was performed using the HumanWhole Genome OnThough the various PP2A family members regulate diverse cellular
functions, very little is known how PP2A might regulate microRNA
expression [36]. We ﬁnd that the suppression of B55α in OCI-AML3
cells had little effect on gene expression (Fig. 9), but the reduction of
B55α expression resulted in the altered expression of a number of miRs
(Fig. 10a and b). The miR most affected was miR-1260a. OCI-AML3 cells
with theB55α shRNAhad N200-fold lessmiR-1260a compared to control
cells (Fig. 10b). Unfortunately, at present the role of this miR in leukemia
is unknown.
Two other miRs that were inhibited when B55α was reduced were
miR-142-3p and miR-142-5p (Fig. 10b). These miRs are of particular
interest as recent genome sequencing analysis of AML patients indicates
that these miRs are mutated in 2% of the patients [13]. The importance
of miR-142-3p in myeloid cell biology is emerging, since this miR
appears to be a regulator of myeloid differentiation [11]. Furthermore,
Dahlhaus and colleagues found that high expression of miR-142-3p
was associated with a good prognosis for AML patients with intermedi-
ate cytogenetics [37]. The induction of miR-191 in response to B55α
suppression in the OCI-AML3 cells was interesting, since elevated levels
of miR-191 suggested a poor prognosis for AML patients [10]. In sum-
mary, B55α appears to be involved in preventing AML disease relapse
by modulating cell survival signaling intermediates (e.g., AKT, PKCα,
MYC, and SRC). Our results also indicate that B55α plays a role in the
regulation of miR expression, although the mechanism involved is not
clear. A model is presented in Fig. 11 depicting the diverse roles
of B55α in regulation of these various processes. Given our data, we
have proposed several novel functions for B55α in the regulation of
signal transduction and gene expression. These cellular effects, as well
as their possible feedback mechanisms, warrant further investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.05.006.Acknowledgements
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